Price Target Changed • Jul 27
Price target increased by 8.9% to US$31.80 Up from US$29.20, the current price target is an average from 5 analysts. New target price is 63% above last closing price of US$19.54. Stock is up 157% over the past year. The company is forecast to post a net loss per share of US$1.01 next year compared to a net loss per share of US$1.32 last year. Announcement • Jul 24
Nuvectis Pharma Announces Approval Of Ciprocopan (NXP100) in China for Treatment Of Paroxysmal Nocturnal Hemoglobinuria Nuvectis Pharma announced that ciprocopan (NXP100) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received a complement inhibitor. It is the first once-daily oral Complement Factor B inhibitor ever approved, anywhere in the world. A second Chinese application, on the same molecule, covering PNH patients who have failed prior C5 inhibitor therapy, remains under review at the same agency. Ciprocopan is a once-daily oral small molecule that shuts down the alternative complement pathway at Factor B, the amplification step that drives red-blood-cell destruction in PNH. Approval rests on a randomized Phase 3 head-to-head study in Chinese treatment-naïve PNH patients, comparing ciprocopan directly against eculizumab (Soliris), the infused C5 inhibitor that has anchored PNH care for nearly two decades. In that study, 59.5% of ciprocopan patients achieved transfusion-free normal hemoglobin, versus 8.3% on eculizumab. Hemoglobin gain from baseline was 5.0 g/dL on ciprocopan versus 2.2 g/dL on eculizumab. Nearly 95% of ciprocopan patients avoided transfusion during the study, versus 69% on eculizumab. No patient discontinued ciprocopan due to an adverse event. Ciprocopan was discovered and developed by Haisco Pharmaceutical Group, which ran the Phase 3 program to completion in-country and filed the NMPA applications. In June, Nuvectis in-licensed exclusive rights to the molecule outside Greater China, India, and certain Southeast Asian territories, for $40 million in upfront and near-term payments and up to $1.421 billion in potential development, regulatory, and commercial milestones, plus tiered royalties. The clinical work is done, the first regulatory approval is in hand, and every ex-China approval, every ex-China dollar of net sales, and every ex-China milestone that follows flows through Nuvectis's own P&L. Recent Insider Transactions • Jul 04
Insider recently bought US$916k worth of stock On the 30th of June, Charles Mosseri-Marlio bought around 50k shares on-market at roughly US$18.32 per share. This transaction amounted to 1.5% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$2.3m more in shares than they have sold in the last 12 months. 
